← Xeris Biopharma Holdings, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $20.2m |
$49.3m
+144.51%
|
$110.2m
+123.72%
|
$163.9m
+48.68%
|
$203.1m
+23.89%
|
$291.8m
+43.72%
|
$335.4m
+14.93%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | $9.3m |
$13.3m
+42.77%
|
$22.6m
+69.95%
|
$28.6m
+26.56%
|
$36.8m
+28.58%
|
$42.6m
+15.58%
|
$45.0m
+5.78%
|
|
| Gross Profit | $10.8m |
$36.0m
+232.15%
|
$87.6m
+143.63%
|
$135.3m
+54.39%
|
$166.2m
+22.89%
|
$249.3m
+49.95%
|
$290.4m
+16.49%
|
|
| Research and Development Expense | $20.9m | $25.2m | $21.0m | $22.3m | $25.6m | $31.2m | $34.8m | |
| Selling, General and Administrative Expense | $73.7m | $125.7m | $137.7m | $146.1m | $163.5m | $182.4m | $208.1m | |
| Amortization of Intangible Assets | $0 | $550k | $10.8m | $10.8m | $10.8m | $10.8m | — | |
| Operating Lease, Expense | — | — | $1.8m | $4.5m | $5.3m | $5.2m | — | |
| Operating expenses: | ||||||||
| Operating Costs and Expenses | $104.0m | $164.7m | $192.2m | $207.9m | $236.7m | $266.9m | — | |
| Operating Income (Loss) | ($83.5m) |
($115.2m)
-37.84%
|
($81.9m)
+28.84%
|
($44.0m)
+46.29%
|
($33.6m)
+23.55%
|
$24.9m
+173.99%
|
$36.6m
+46.98%
|
|
| Interest Income, Other | $3.0m | $313k | $2.6m | $4.8m | $5.3m | $4.7m | $5.3m | |
| Other Nonoperating Income (Expense) | ($7.7m) | ($7.6m) | ($14.1m) | ($19.5m) | ($23.5m) | ($24.3m) | — | |
| Interest Expense (non-operating) | $10.7m | $7.2m | $15.3m | $26.6m | $30.5m | $29.1m | $28.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $83.5m | $115.2m | $81.9m | ($67.3m) | ($78.4m) | ($45.9m) | ($17.2m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $83.5m | $115.2m | $81.9m | ($63.5m) | ($57.1m) | $554k | ($17.2m) | |
| Income Tax Expense (Benefit) | ($110k) | $0 | ($1.4m) | ($1.2m) | ($2.3m) | $0 | $0 | |
| Net Income (Loss) Attributable to Parent | ($91.1m) |
($122.7m)
-34.66%
|
($94.7m)
+22.87%
|
($62.3m)
+34.23%
|
($54.8m)
+11.92%
|
$554k
+101.01%
|
($17.2m)
-3198.38%
|
|
| Earnings Per Share, Basic | ($2.14) | ($1.55) | ($0.70) | ($0.45) | ($0.37) | $0.00 | ($0.10) | |
| Earnings Per Share, Diluted | ($2.14) | ($1.55) | ($0.70) | ($0.45) | ($0.37) | $0.00 | ($0.10) | |
| Weighted Average Number of Shares Outstanding, Basic | — | 79.0m | 135.6m | 137.7m | 146.8m | 160.4m | 168.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 79.0m | 135.6m | 137.7m | 146.8m | 172.7m | 180.6m | |
| Additional Financial Items | ||||||||
| Income (Loss) Attributable to Parent, before Tax | ($91.2m) | ($122.7m) | ($96.1m) | ($63.5m) | ($57.1m) | $554k | — |